Mode
Text Size
Log in / Sign up

Review of preclinical FH12-based Sandwich-ELISA for mucormycosis detection

Review of preclinical FH12-based Sandwich-ELISA for mucormycosis detection
Photo by Navy Medicine / Unsplash
Key Takeaway
Note this preclinical review does not establish clinical efficacy for mucormycosis diagnosis in humans.

This publication is a preclinical review evaluating an FH12-based Sandwich-ELISA for the detection of mucormycosis. The scope covers the analytical performance of the assay in a preclinical setting rather than a clinical trial in humans.

Key synthesized findings indicate the assay demonstrates pan-Mucorales specificity with no cross-reactivity with other clinically relevant yeasts and moulds. The epitope is described as periodate-insensitive and moderately heat-stable. The limit of detection is reported at pg/mL to low ng/mL levels. The method successfully identified the EPS biomarker in patient tissue homogenates.

The authors note that this is a preclinical development and evaluation, not a clinical trial in humans. Consequently, the potential to be used as a laboratory-based adjunct diagnostic test for the detection of mucormycosis in humans remains theoretical based on this data. No adverse events or tolerability data are reported because the study was not conducted in humans.

Study Details

EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Background: Mucormycosis is a rapidly progressive and often fatal invasive fungal infection caused by moulds in the order, Mucorales. Early diagnosis is essential for effective clinical management; however, conventional diagnostic approaches such as culture and histopathology are slow, insensitive, and require specialist mycological expertise. Although molecular methods are available for disease detection, they are not widely accessible. At present, no enzyme immunoassay (EIA) exists for the detection of mucormycosis. Methods: A murine IgG1 monoclonal antibody (mAb), FH12, was generated against extracellular polysaccharides (EPSs) produced by Mucorales pathogens during active growth. The antibody was characterised for specificity, epitope stability, and antigen localisation using ELISA, immunoblotting, and immunofluorescence techniques. The mAb was incorporated into a Sandwich-ELISA and evaluated using culture filtrates, purified EPSs spiked into human serum, and tissue homogenates from a patient with cutaneous mucormycosis caused by Lichtheimia ramosa. Results: mAb FH12 demonstrated pan-Mucorales specificity and no cross-reactivity with other clinically relevant yeasts and moulds. The epitope recognised by FH12 is periodate-insensitive and moderately heat-stable. The Sandwich-ELISA detected EPS antigens in human serum with limits of detection ranging from pg/mL to low ng/mL levels, and successfully identified the EPS biomarker in patient tissue homogenates. Conclusion: The FH12-based Sandwich-ELISA shows high sensitivity and specificity, and has the potential to be used as a laboratory-based adjunct diagnostic test for the detection of mucormycosis in humans.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.